secwatch.observer — SEC 8-K summary
======================================

Issuer:     VERACYTE, INC. (VCYT)
CIK:        0001384101
Form:       8-K
Filed at:   2021-11-09T23:59:59+00:00
Accession:  0001384101-21-000173
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Veracyte Q3 2021 revenue $60.4M (+94% YoY); raises FY guidance to $210-218M
---------------------------------------------------------------------------

- Total revenue $60.4M, up 94% YoY; volume 20,972 tests (+79%).
- Net loss $14.1M ($0.20 EPS) vs $4.1M loss Q3 2020; includes HalioDx costs.
- Completed HalioDx acquisition for $321M; launched Percepta Nasal Swab and Decipher Bladder tests.
- FY 2021 revenue guidance raised to $210-218M from $200-208M, implying 79-86% growth.
- Cash $164M at quarter-end; operating cash used $1.4M incl. $3.9M acquisition expenses.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1384101/000138410121000173/0001384101-21-000173-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1384101/000138410121000173/vcyt-20211109.htm
  HTML page:      https://secwatch.observer/filing/0001384101-21-000173

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer